Experimental combo therapy for advanced cancer shows early promise but trial cut short
NCT ID NCT05491317
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This early-stage trial tested a new drug (GEN1042) combined with radiation, with or without another immunotherapy (pembrolizumab), in people with metastatic solid tumors that had no standard treatment options. The goal was to see if the combination was safe and could shrink tumors, including those not directly treated with radiation. Only 13 people took part before the study was stopped early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Leon Berard
Lyon, 69008, France
-
Institut Gustave Roussy
Villejuif, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can your own immune cells fight advanced cancer?
- Can a new pill outsmart RAS-Mutant cancers?
- Could a personal coach at home boost energy for cancer patients?
- Personalized maintenance therapy: a smarter way to treat advanced cancer?
- Can a radioactive antibody light up hidden cancers on PET scans?